Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages 2004-2010

  Van Cutsem, Eric ^{a,b,c,d,e,f,g,h,i,j,k}   Bajetta, Emilio ^{a,b,c,d,e,f,g,h,i,j,k}   Valle, Juan ^{a,b,c,d,e,f,g,h,i,j,k}   Köhne, Claus Henning ^{a,b,c,d,e,f,g,h,i,j,k}   Hecht, J Randolph ^{a,b,c,d,e,f,g,h,i,j,k}   Moore, Malcolm ^{a,b,c,d,e,f,g,h,i,j,k}   Germond, Colin ^{a,b,c,d,e,f,g,h,i,j,k}   Berg, William ^{a,b,c,d,e,f,g,h,i,j,k}   Chen, Bee Lian ^{a,b,c,d,e,f,g,h,i,j,k}   Jalava, Tarja ^{a,b,c,d,e,f,g,h,i,j,k}   Lebwohl, David ^{a,b,c,d,e,f,g,h,i,j,k}   Meinhardt, Gerold ^{a,b,c,d,e,f,g,h,i,j,k}   Laurent, Dirk ^{a,b,c,d,e,f,g,h,i,j,k}   Lin, Edward ^{a,b,c,d,e,f,g,h,i,j,k}  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e BAYER PHARMA AG   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h Northeastern Ontario Regional Cancer Centre   (Canada)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j Bayer Schering Pharma Oy   (Finland)

^k SEATTLE CANCER CARE ALLIANCE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LACTATE DEHYDROGENASE; OXALIPLATIN; PLACEBO; VATALANIB;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STEADY STATE; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PHTHALAZINES; PLACEBOS; PYRIDINES;

EID: 79956297102     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.5436     Document Type: Article

References (24)

1. Ferlay J, Autier P, Boniol M, et al: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592, 2007
2. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 355:1041-1047, 2000 (Pubitemid 30162806)
3. De Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000 (Pubitemid 30644117)
4. Koehne CH, Van Cutsem E, Wils J, et al: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23:4856-4865, 2005 (Pubitemid 46223990)
5. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
6. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 25:1539-1544, 2007 (Pubitemid 46733080)
7. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
8. Hess-Stumpp H, Haberey M, Thierauch KH: PTK787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 6:550-557, 2005 (Pubitemid 40868144)
9. Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189, 2000 (Pubitemid 30225181)
10. Drevs J, Hofmann I, Hugenschmidt H, et al: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60:4819-4824, 2000
11. Morgan B, Thomas AL, Drevs J, et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 21:3955-3964, 2003 (Pubitemid 46606209)
12. Mross K, Drevs J, Müller M, et al: Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 41:1291-1299, 2005 (Pubitemid 40813005)
13. Joensuu H, De Braud F, Coco P, et al: Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 19:173-177, 2008
14. de Bazelaire C, Alsop DC, George D, et al: Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 14:5548-5554, 2008
15. Thomas AL, Trarbach T, Bartel C, et al: A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Ann Oncol 18:782-788, 2007 (Pubitemid 46523285)
16. Los M, Roodhart JML, Voest EE: Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12:443-450, 2007 (Pubitemid 46698722)
17. Lee L, Sharma S, Morgan B, et al: Biomarkers for assessment of pharmacological activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): Translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases Cancer Chemother Pharmacol 57:761-771, 2006
18. Peterson AC, Swiger S, Stadler WM, et al: Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 10:4048-4054, 2004 (Pubitemid 38812480)
19. Jost LM, Gschwind HP, Jalava T, et al: Metabolism and disposition of vatalanib (PTK787/ZK- 222584) in cancer patients. Drug Metab Dispos 34:1817-1828, 2006
20. Harris AL: Hypoxia: A key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47, 2002
21. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Lactate dehydrogenase 5 expression in operable colorectal cancer: Strong association with survival and activated vascular endothelial growth factor pathway: A report of the tumour angiogenesis research group. J Clin Oncol 24: 4301-4308, 2006 (Pubitemid 46630788)
22. Laurie SA, Gauthier I, Arnold A, et al: Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 26:1871-1878, 2008
23. Glusker P, Recht L, Lane B: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354:980-982, 2006
24. Martín G, Bellido L, Cruz JJ: Reversible Posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 25:3559, 2007 (Pubitemid 47310905)